MM+M’s Post

Valneva and Pfizer Present Results from the P-II (VLA15-221) Study of VLA15 Vaccine for Lyme Disease #valneva #pfizer #vla15 #lymedisease #clinicaltrial #phase2 #vaccine #immunogenicity #phase3

Thoughts on this? >> GSK unintimidated by RSV vaccine uptake challenges, Shingrix US sales drop >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #biotech #productmarketing

Thoughts on this? >> Pfizer and Valneva say second Lyme booster led to 'strong' responses, target 2026 FDA submission >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #productmarketing #biotech #pharma

Thoughts on this? >> Pfizer and Valneva say second Lyme booster led to 'strong' responses, target 2026 FDA submission >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #pharmaceutical #healthcare

💉 Recently, Valneva announced that the US FDA has approved IXCHIQ, a single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV. With this US approval, IXCHIQ becomes the world’s first licensed chikungunya vaccine available to address this unmet medical need. 🔎 Leveraging our Patent Analytics module, we have identified that Merck is the top patent owner related to Chikungunya fever, but Valneva has taken a significant market lead following the FDA’s approval of IXCHIQ - the first chikungunya vaccine. 💡 GlobalData Patent module delivers specialized expertise in the pharmaceutical industry, harnessing our unique data, insights, and analytics. Our tailored approach and deliverables empower you with comprehensive answers to your specific patent-related questions. Reach out directly to learn more about our patent capabilities or to have a chat! #chikungunya #vaccine #fdaapproval #lifesciences #biotechnology

I've written some blogs about important considerations for Patient Recruitment and Patient Retention when preparing for and conducting flu clinical trials. Feel free to check out the first blog post on patient-focused considerations here: https://bit.ly/3WVnVEm

🌟 Is Your Influenza Clinical Trial Ready for Flu Season? 🌟 Flu season is fast approaching, bringing unique challenges to respiratory clinical trials. Is your study prepared to recruit and retain patients effectively? In our latest blog, "Key Considerations for Patient Recruitment and Retention - Part #1," we explore essential strategies to ensure your trial stands out. 🔍 Highlights: ⭐️Patient Awareness: Learn how to increase trial visibility and engage the local community. ⭐️Community Outreach: Discover effective methods to reach potential participants. ⭐️Referral Networks: Optimize your network to maximize patient recruitment. 🚀 Boost Your Recruitment Success! Join us as we delve into Innovative Trials' proven strategies that have led to a 297% increase in patient randomization rates. Don’t miss out on practical tips and expert insights to prepare your trial for the upcoming flu season. 📞 Special Offer: Book a free 30-minute strategy call with our CEO, Kate Shaw, to get personalized advice on making your influenza study a success Read the full blog now and get ahead this flu season!👉 https://bit.ly/3WVnVEm #ClinicalTrials #PatientEngagement #InnovativeSolutions #ClinicalResearch #PharmaExcellence #InfluenzaStudy #Covid19 #InnovativeTrials #FluStudy #EffectiveSupport #patientrecruitment #pharma #pharmaceutical #pharmaceuticals #pharmaindustry #pharmaceuticalindustry #patientaccess #bootsontheground #communityengagement

The article "Insights+: The US FDA New Drug Approvals in September 2023" from PharmaShots provides insights into the new drug approvals by the US FDA in September 2023. New drugs mentioned include: 1. BioLineRx’s Aphexda (motixafortide) + Filgrastim for Multiple Myeloma 2. GSK 's Ojjaara (momelotinib) for Myelofibrosis Patients with Anemia 3. Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) for Adults with Chronic Kidney Disease 4. Saptalis Pharmaceuticals’ Likmez (ATI-1501) for Antimicrobial Infections 5. Takeda's Entyvio (vedolizumab) for Subcutaneous Administration to Treat Active Ulcerative Colitis 6. Viatris and Ocuphire Pharma’s Ryzumvl (Phentolamine Ophthalmic Solution) for Pharmacologically-Induced Mydriasis 7. Fabre-Kramer Pharmaceuticals’ Exxua for the Treatment of Major Depressive Disorder in Adults 8. Amicus Therapeutics’ Pombiliti (cipaglucosidase alfa-atga) + Opfolda for Pompe Disease 9. Novo Nordisk’ Rivfloza (nedosiran) for Children Aged ≥9 Years and Adults with Primary Hyperoxaluria Type 1 Article link: https://lnkd.in/ge5YJSQT #USFDA #NewDrug #DrugDevelopment #Pharmaceutical

#Preventive_Vaccines Market Share Charges Ahead with Huge Growth 2023-2032 https://bit.ly/3HeFAiC #Biological treatments that aim to #prevent infectious #illnesses are known as preventive #vaccines. The preventive vaccine either #increases immunity or promotes the development of #antibodies #against possible infectious #agents. Most vaccines are mandatorily given to #humans at the infant #stage. Sanofi Pfizer Novavax Johnson & Johnson GlaxoSmithKline Consumer Healthcare, L.P. Daiichi Sankyo, Inc. Emergent BioSolutions AstraZeneca TakedaPharmaceutical Nordics AB #healthcare #share #development #technologies #preventivemaintenance #healthcareindustry

Vaccine Milestone: FDA Grants Priority Review to Bavarian Nordic’s Chikungunya Vaccine BLA The FDA has granted priority review to Bavarian Nordic's Biologics License Application for its chikungunya vaccine candidate, CHIKV VLP, a virus-like particle-based vaccine for individuals aged 12 and older. With a decision expected by February 2025, this accelerated review could lead to the first approved vaccine for chikungunya virus, a mosquito-borne disease affecting over 100 countries. The European Medicines Agency is also assessing the vaccine for potential approval by mid-2025. CHIKV VLP's single-dose format and promising clinical trial results reflect Bavarian Nordic's expertise and could provide a critical tool in combating global outbreaks and reducing the long-term effects of chikungunya. For more details please click the link! https://lnkd.in/dQWGZvy4 #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical